126 related articles for article (PubMed ID: 25194954)
1. The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease.
Brewer GJ
J Trace Elem Med Biol; 2014 Oct; 28(4):372-8. PubMed ID: 25194954
[TBL] [Abstract][Full Text] [Related]
2. Anticopper therapy against cancer and diseases of inflammation and fibrosis.
Brewer GJ
Drug Discov Today; 2005 Aug; 10(16):1103-9. PubMed ID: 16182195
[TBL] [Abstract][Full Text] [Related]
3. Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models.
Hou G; Dick R; Zeng C; Brewer GJ
Transl Res; 2006 Dec; 148(6):309-14. PubMed ID: 17162252
[TBL] [Abstract][Full Text] [Related]
4. Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer.
Brewer GJ
Curr Cancer Drug Targets; 2005 May; 5(3):195-202. PubMed ID: 15892619
[TBL] [Abstract][Full Text] [Related]
5. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
Brewer GJ; Merajver SD
Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
[TBL] [Abstract][Full Text] [Related]
6. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.
Brewer GJ; Dick RD; Grover DK; LeClaire V; Tseng M; Wicha M; Pienta K; Redman BG; Jahan T; Sondak VK; Strawderman M; LeCarpentier G; Merajver SD
Clin Cancer Res; 2000 Jan; 6(1):1-10. PubMed ID: 10656425
[TBL] [Abstract][Full Text] [Related]
7. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.
Brewer GJ
J Cell Mol Med; 2003; 7(1):11-20. PubMed ID: 12767257
[TBL] [Abstract][Full Text] [Related]
8. The use of copper-lowering therapy with tetrathiomolybdate in medicine.
Brewer GJ
Expert Opin Investig Drugs; 2009 Jan; 18(1):89-97. PubMed ID: 19053885
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.
Redman BG; Esper P; Pan Q; Dunn RL; Hussain HK; Chenevert T; Brewer GJ; Merajver SD
Clin Cancer Res; 2003 May; 9(5):1666-72. PubMed ID: 12738719
[TBL] [Abstract][Full Text] [Related]
10. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease.
Brewer GJ
Exp Biol Med (Maywood); 2001 Jul; 226(7):665-73. PubMed ID: 11444102
[TBL] [Abstract][Full Text] [Related]
11. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
Brewer GJ
Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis.
Brewer GJ; Dick R; Ullenbruch MR; Jin H; Phan SH
J Inorg Biochem; 2004 Dec; 98(12):2160-7. PubMed ID: 15541506
[TBL] [Abstract][Full Text] [Related]
13. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.
Brewer GJ; Ullenbruch MR; Dick R; Olivarez L; Phan SH
J Lab Clin Med; 2003 Mar; 141(3):210-6. PubMed ID: 12624602
[TBL] [Abstract][Full Text] [Related]
14. Copper chelation with tetrathiomolybdate suppresses adjuvant-induced arthritis and inflammation-associated cachexia in rats.
Omoto A; Kawahito Y; Prudovsky I; Tubouchi Y; Kimura M; Ishino H; Wada M; Yoshida M; Kohno M; Yoshimura R; Yoshikawa T; Sano H
Arthritis Res Ther; 2005; 7(6):R1174-82. PubMed ID: 16277669
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis.
Hou G; Abrams GD; Dick R; Brewer GJ
Transl Res; 2008 Nov; 152(5):239-44. PubMed ID: 19010295
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer.
Henry NL; Dunn R; Merjaver S; Pan Q; Pienta KJ; Brewer G; Smith DC
Oncology; 2006; 71(3-4):168-75. PubMed ID: 17641535
[TBL] [Abstract][Full Text] [Related]
17. Antitumor and antiinflammatory effects of tetrathiotungstate in comparison with tetrathiomolybdate.
Hou G; Dick R; Zeng C; Brewer GJ
Transl Res; 2007 May; 149(5):260-4. PubMed ID: 17466925
[TBL] [Abstract][Full Text] [Related]
18. Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm.
Khan G; Merajver S
Expert Opin Investig Drugs; 2009 Apr; 18(4):541-8. PubMed ID: 19335282
[TBL] [Abstract][Full Text] [Related]
19. Control of copper status for cancer therapy.
Goodman VL; Brewer GJ; Merajver SD
Curr Cancer Drug Targets; 2005 Nov; 5(7):543-9. PubMed ID: 16305350
[TBL] [Abstract][Full Text] [Related]
20. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model.
Brewer GJ; Dick R; Zeng C; Hou G
J Inorg Biochem; 2006 May; 100(5-6):927-30. PubMed ID: 16321443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
